Condensed Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Series A Preferred Stock Atrin Pharmaceuticals, Inc	Series A Preferred Stock	Common Stock Atrin Pharmaceuticals, Inc	Common Stock	Additional Paid-in capital Atrin Pharmaceuticals, Inc	Additional Paid-in capital	Other comprehensive loss	Accumulated deficit	Atrin Pharmaceuticals, Inc	Total
Equity, beginning balance at Dec. 31, 2020				$ 21,187		$ 231,418,356	$ (10,037,261)	$ (144,007,075)		$ 77,395,207
Equity, beginning balance (in shares) at Dec. 31, 2020				21,186,827
Increase (Decrease) in Stockholders' Equity
Stock based compensation						1,822,562				1,822,562
Foreign currency translation							(402,850)			(402,850)
Net loss								(9,668,755)		(9,668,755)
Equity, ending balance at Mar. 31, 2021				$ 21,187		233,240,918	(10,440,111)	(153,675,830)		69,146,164
Equity, ending balance (in shares) at Mar. 31, 2021				21,186,827
Equity, beginning balance at Dec. 31, 2020				$ 21,187		231,418,356	(10,037,261)	(144,007,075)		77,395,207
Equity, beginning balance (in shares) at Dec. 31, 2020				21,186,827
Increase (Decrease) in Stockholders' Equity
Foreign currency translation										(209,830)
Net loss										(19,919,768)
Equity, ending balance at Jun. 30, 2021				$ 21,187		235,104,416	(10,247,091)	(163,926,843)		60,951,669
Equity, ending balance (in shares) at Jun. 30, 2021				21,186,827
Equity, beginning balance at Mar. 31, 2021				$ 21,187		233,240,918	(10,440,111)	(153,675,830)		69,146,164
Equity, beginning balance (in shares) at Mar. 31, 2021				21,186,827
Increase (Decrease) in Stockholders' Equity
Stock based compensation						1,863,498				1,863,498
Foreign currency translation							193,020			193,020
Net loss								(10,251,013)		(10,251,013)
Equity, ending balance at Jun. 30, 2021				$ 21,187		235,104,416	(10,247,091)	(163,926,843)		60,951,669
Equity, ending balance (in shares) at Jun. 30, 2021				21,186,827
Temporary equity, beginning balance (in shares) at Dec. 31, 2021		0
Equity, beginning balance at Dec. 31, 2021				$ 21,859		240,978,439	(10,358,956)	(181,134,378)		49,506,964
Equity, beginning balance (in shares) at Dec. 31, 2021				21,859,413
Increase (Decrease) in Stockholders' Equity
Vesting of restricted stock units				$ 115		(115)
Vesting of restricted stock units (in shares)				114,889
Stock based compensation						2,084,060				2,084,060
Foreign currency translation							(65,505)			(65,505)
Net loss								(7,936,693)		(7,936,693)
Equity, ending balance at Mar. 31, 2022				$ 21,974		243,062,384	(10,424,461)	(189,071,071)		43,588,826
Equity, ending balance (in shares) at Mar. 31, 2022				21,974,302
Temporary equity, beginning balance (in shares) at Dec. 31, 2021		0
Temporary equity, ending balance (in shares) at Jun. 30, 2022		2,949,630
Temporary equity, ending balance at Jun. 30, 2022		$ 68,777,468
Equity, beginning balance at Dec. 31, 2021				$ 21,859		240,978,439	(10,358,956)	(181,134,378)		49,506,964
Equity, beginning balance (in shares) at Dec. 31, 2021				21,859,413
Increase (Decrease) in Stockholders' Equity
Foreign currency translation										92,150
Net loss										(106,195,167)
Equity, ending balance at Jun. 30, 2022				$ 23,401		261,795,121	(10,266,806)	(287,329,545)		(35,777,829)
Equity, ending balance (in shares) at Jun. 30, 2022				23,401,846
Increase (Decrease) in Temporary Equity
Issuance of preferred stock upon acquisition of Atrin	$ 68,777,468
Issuance of preferred stock upon acquisition of Atrin (in shares)	2,949,630
Temporary equity, ending balance (in shares) at Jun. 30, 2022		2,949,630
Temporary equity, ending balance at Jun. 30, 2022		$ 68,777,468
Equity, beginning balance at Mar. 31, 2022				$ 21,974		243,062,384	(10,424,461)	(189,071,071)		43,588,826
Equity, beginning balance (in shares) at Mar. 31, 2022				21,974,302
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon acquisition of Atrin			$ 1,117		$ 1,328,582				$ 1,329,699
Issuance of common stock upon acquisition of Atrin (in shares)			1,117,394
Value of assumed stock options						2,602,850				2,602,850
Vesting of restricted stock units				$ 310		(310)
Vesting of restricted stock units (in shares)				310,150
Stock based compensation						14,801,615				14,801,615
Foreign currency translation							157,655			157,655
Net loss								(98,258,474)		(98,258,474)
Equity, ending balance at Jun. 30, 2022				$ 23,401		$ 261,795,121	$ (10,266,806)	$ (287,329,545)		$ (35,777,829)
Equity, ending balance (in shares) at Jun. 30, 2022				23,401,846